Technology ID
TAB-3714
Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS)
E-Numbers
E-009-2019-0
Lead Inventor
Sati, Pascal (NINDS)
Co-Inventors
Reich, Daniel (NINDS)
Patil, Sunil (Siemens Medical Solutions USA)
Applications
Software / Apps
Diagnostics
Therapeutic Areas
Ophthalmology
Oncology
Neurology
Infectious Disease
Endocrinology
Dental
Cardiology
Research Products
Research Equipment
Computational models/software
Lead IC
NINDS
ICs
NINDS
This technology includes an automated and non-invasive assessment system called Automated Identification of subjects at risks of Multiple Sclerosis (AIMS) to assist clinicians in their diagnostic evaluation. A focus of AIMS is the ‘central vein sign’ (and other radiological findings). The methodology is composed of the following features:
- Ultra-fast high-resolution susceptibility imaging of the brain using novel MRI technique called 3D segmented echo-planar-imaging
- Novel MRI contrasts (e.g., FLAIR*, QSM) using advanced processing
- Fully automated detection for brain lesions, central vein sign and lesion rims, using novel statistical/machine-learning techniques
Commercial Applications
There are no commercially-available tools for automatically detecting central veins in cerebral plaques and assisting clinicians in the diagnosis of MS using radiological findings.
Competitive Advantages
AIMS is the first non-invasive automated assessment of the ‘central vein sign’ (small veins inside lesions) in patient brains.
Licensing Contact: